Profil bibliographique

Enrique López Rosas

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

15Publications signalées

1032Citations signalées

0Affiliations récentes

Domaines associés

Lipoproteins and Cardiovascular HealthDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsHeart Failure Treatment and ManagementAtrial Fibrillation Management and Outcomes

Publications récentes

2026 articleOpenAlex

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial

Michelle Welch, Thomas Forst, Weiping Jia, Pedro Orozco del Pino et autres

1 citationThe Lancet

Accès ouvert 2026 articleOpenAlex

The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial

Francesco Fioretti, Faı̈ez Zannad, Irina Barash, Stefano Corda et autres

1 citationEuropean Journal of Heart Failure

Accès ouvert 2025 articleOpenAlex

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler, Ciaran J. McMullan et autres

44 citationsThe Lancet

Accès ouvert 2025 articleOpenAlex

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom, Irina Barash et autres

81 citationsThe Lancet

Accès ouvert 2025 articleOpenAlex

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres

25 citationsCirculation

Accès ouvert 2024 articleOpenAlex

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

24 citationsEuropean Heart Journal - Cardiovascular Pharmacotherapy

Accès ouvert 2022 articleOpenAlex

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Sylvia Haas, A. John Camm, Harald Darius, Jan Steffel et autres

12 citationsClinical Research in Cardiology

Accès ouvert 2022 articleOpenAlex

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

125 citationsCirculation

Accès ouvert 2021 articleOpenAlex

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Manvelian et autres

144 citationsJournal of the American College of Cardiology

Accès ouvert 2021 articleOpenAlex

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner, Deepak L. Bhatt et autres

40 citationsDiabetes Care

Accès ouvert 2020 articleOpenAlex

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa, Frank Edelmann et autres

84 citationsJAMA Cardiology

Accès ouvert 2019 articleOpenAlex

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie T. Baccara‐Dinet et autres

331 citationsThe Lancet Diabetes & Endocrinology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.